Bevacizumab can suppress various VEGF-driven cellular responses, including cell proliferation, survival, migration, and tissue factor production.254 Gaykema et al. performed a clinical feasibility study on the application of [89Zr]Zr-N-sucDf-bevacizumab PET/CT for diagnosing BC patients for the first time.255 The results revealed that tumour uptake of [89Zr]Zr-N-sucDf-bevacizumab was observed in 96.1% of the primary lesions, and the SUVmax in the tumours was greater (1.85 ± 1.22) than that in the normal breasts (0.59 ± 0.37). The gene discussed is VEGFA; the disease is neoplasm.